论文部分内容阅读
目的探肝动脉化疗栓塞术(TACE)联合索拉菲尼治疗原发性肝癌的疗效。方法选取2013年4月至2016年2月收治的88例原发性肝癌患者。将所有患者随机分为两组:实验组37例,对照组51例。实验组行TACE联合索拉菲尼治疗,对照组仅行TACE治疗,观察实验组及对照组的临床疗效及不良反应发生情况。结果在治疗期间两组患者的血小板减少、白细胞减少、肝功能损伤、胃肠道反应等不良反应发生率比较差异均无统计学意义(χ2=0.885、0.918、2.267、0.449,P均>0.05)。治疗有效率及疾病控制率实验组分别为73.0%和91.9%,对照组分别为35.3%和58.8%,实验组显著高于对照组,差异有统计学意义(χ2=28.623、29.493,P均<0.01)。结论相比于单纯行TACE术治疗,TACE联合索拉菲尼治疗原发性肝癌,能有效控制病情恶化,延缓肿瘤进展,从而延长患者生存期,且索拉非尼不会增加患者不良反应发生率,安全性好。
Objective To investigate the therapeutic effect of transcatheter arterial chemoembolization (TACE) combined with sorafenib on primary liver cancer. Methods Eighty-eight patients with primary liver cancer who were admitted from April 2013 to February 2016 were enrolled. All patients were randomly divided into two groups: experimental group 37 cases, control group 51 cases. The experimental group TACE combined with sorafenib treatment, the control group only TACE treatment, the experimental group and control group were observed the clinical efficacy and adverse reactions. Results There was no significant difference in the incidence of adverse reactions such as thrombocytopenia, leukopenia, liver function impairment and gastrointestinal reactions between the two groups during the treatment (χ2 = 0.885,0.918,2.267,0.449, P> 0.05) . The treatment efficiency and disease control rate were 73.0% and 91.9% in the experimental group and 35.3% and 58.8% in the control group respectively, which were significantly higher in the experimental group than in the control group (χ2 = 28.623, 29.493, P < 0.01). Conclusion TACE combined with sorafenib compared with simple TACE treatment of primary liver cancer, can effectively control the disease progression, delay the progression of the tumor, thereby prolonging the survival of patients, and sorafenib does not increase the adverse reactions in patients Rate, good security.